Response Evaluation and Follow-Up by Imaging in Brain Tumours

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-030-38261-2_21
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• PET imaging in patients with brain metastasis-report of the RANO/PET group.

  2019cited by this paper
• Metastatic Atypical and Anaplastic Meningioma: A Case Series and Review of the Literature.

  2017cited by this paper
• Improved Detection of Transosseous Meningiomas Using 68Ga-DOTATATE PET/CT Compared with Contrast-Enhanced MRI

  2017cited by this paper
• PET imaging in patients with meningioma—report of the RANO/PET Group

  2017cited by this paper
• The Risk of Radiation-Induced Tumors or Malignant Transformation After Single-Fraction Intracranial Radiosurgery: Results Based on a 25-Year Experience.

  2017cited by this paper
• Cerebral Cortex Regions Selectively Vulnerable to Radiation Dose-Dependent Atrophy.

  2017cited by this paper
• PET/MRI: Multiparametric imaging of brain tumors.

  2017cited by this paper
• Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy

  2016cited by this paper
• The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

  2016cited by this paper
• Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy

  2016cited by this paper
• Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases.

  2016cited by this paper
• Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.

  2016cited by this paper
• Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.

  2016cited by this paper
• Neuro-oncology: Amino acid PET for brain tumours — ready for the clinic?

  2016cited by this paper
• Early and late effects of radiochemotherapy on cerebral blood flow in glioblastoma patients measured with non-invasive perfusion MRI.

  2016cited by this paper
• Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis.

  2016cited by this paper
• The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy

  2016cited by this paper
• Long-term evaluation of the effect of hypofractionated high-energy proton treatment of benign meningiomas by means of 11C-l-methionine positron emission tomography

  2016cited by this paper
• Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

  2016cited by this paper
• 18F-Fluorocholine PET/CT as a complementary tool in the follow-up of low-grade glioma: diagnostic accuracy and clinical utility

  2015cited by this paper
• Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM

  2015cited by this paper
• Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.

  2015cited by this paper
• Comparison of Apparent Diffusion Coefficient and Intravoxel Incoherent Motion for Differentiating among Glioblastoma, Metastasis, and Lymphoma Focusing on Diffusion-Related Parameter

  2015cited by this paper
• Response assessment criteria for brain metastases: proposal from the RANO group.

  2015cited by this paper
• The 18-kDa Mitochondrial Translocator Protein in Human Gliomas: An 11C-(R)PK11195 PET Imaging and Neuropathology Study

  2015cited by this paper
• Stroke-like Migraine Attacks after Radiation Therapy Syndrome

  2015cited by this paper
• Neurocognitive Deficits After Radiation Therapy for Brain Malignancies

  2015cited by this paper
• Increased 68Ga-DOTATATE Uptake in PET Imaging Discriminates Meningioma and Tumor-Free Tissue

  2015cited by this paper
• Benign versus atypical meningiomas: risk factors predicting recurrence.

  2015cited by this paper
• The use of 18F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma

  2015cited by this paper
• High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2014cited by this paper
• Neurological imaging of brain damages after radiotherapy and/or chimiotherapy.

  2014cited by this paper
• Radionecrosis of malignant glioma and cerebral metastasis: a diagnostic challenge in MRI.

  2014cited by this paper
• Stereotactic radiosurgery in the treatment of brain metastases: the current evidence.

  2014cited by this paper
• Clinical applications for diffusion magnetic resonance imaging in radiotherapy.

  2014cited by this paper
• Assesment of perfusion in glial tumors with arterial spin labeling; comparison with dynamic susceptibility contrast method.

  2014cited by this paper
• Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy

  2014cited by this paper
• 18F-FLT    and 18F-FDOPA PET kinetics in recurrent brain tumors

  2014cited by this paper
• [18F]Fluoroethyltyrosine–Positron Emission Tomography-Based Therapy Monitoring after Stereotactic Iodine-125 Brachytherapy in Patients with Recurrent High-Grade Glioma

  2013cited by this paper
• 18F-FDG PET in the Diagnosis and Treatment of Primary Central Nervous System Lymphoma

  2013cited by this paper
• Chemical Exchange Saturation Transfer (CEST) Imaging: Description of Technique and Potential Clinical Applications

  2013cited by this paper
• Extent of perilesional edema differentiates radionecrosis from tumor recurrence following stereotactic radiosurgery for brain metastases.

  2013cited by this paper
• Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.

  2013cited by this paper
• The Use of O-(2-18F-Fluoroethyl)-l-Tyrosine PET for Treatment Management of Bevacizumab and Irinotecan in Patients with Recurrent High-Grade Glioma: A Cost-Effectiveness Analysis

  2013cited by this paper
• Bevacizumab as salvage therapy for progressive brain stem gliomas.

  2013cited by this paper
• The Translocator Protein Radioligand 18F-DPA-714 Monitors Antitumor Effect of Erufosine in a Rat 9L Intracranial Glioma Model

  2013cited by this paper
• Validation of 18F-FDG PET at Conventional and Delayed Intervals for the Discrimination of High-Grade From Low-Grade Gliomas: A Stereotactic PET and MRI Study

  2013cited by this paper
• Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI

  2012cited by this paper
• Brain tumors.

  2012cited by this paper
• A hitchhiker's guide to diffusion tensor imaging

  2012cited by this paper
• FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.

  2012cited by this paper
• Evaluation of brain tumors using dynamic 11C-methionine-PET

  2012cited by this paper
• Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-l-tyrosine PET in comparison to MRI

  2012cited by this paper
• Atypical and anaplastic meningiomas treated with bevacizumab

  2012cited by this paper
• Radiation-Induced Intratumoral Necrosis and Peritumoral Edema after Gamma Knife Radiosurgery for Intracranial Meningiomas

  2012cited by this paper
• F-18 FDG PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI.

  2012cited by this paper
• Assessment of Treatment Response in Patients with Glioblastoma Using O-(2-18F-Fluoroethyl)-l-Tyrosine PET in Comparison to MRI

  2012cited by this paper
• Comparison of 11C-Methionine PET and 18F-FDG PET in Patients with Primary Central Nervous System Lymphoma

  2011cited by this paper
• Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation Status

  2011cited by this paper
• Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.

  2011cited by this paper
• Comparison of C-11 Methionine and C-11 Choline for PET Imaging of Brain Metastases: A Prospective Pilot Study

  2011cited by this paper
• Treatment of steroid refractory, Gamma Knife related radiation necrosis with bevacizumab: case report and review of the literature.

  2011cited by this paper
• Central Nervous System Lymphoma: Characteristic Findings on Traditional and Advanced Imaging

  2011cited by this paper
• Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study

  2011cited by this paper
• MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury.

  2011cited by this paper
• Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol versus gadoteridol: A pilot study

  2011cited by this paper
• Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme.

  2011cited by this paper
• Response Assessment in Neuro-Oncology

  2011cited by this paper
• Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.

  2011cited by this paper
• Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for Glioma Grading: Assessment of Individual Probability of Malignancy

  2011cited by this paper
• Glioma recurrence versus radiation necrosis? A pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced MRI, and FDG-PET imaging.

  2010cited by this paper
• Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging

  2010cited by this paper
• Management of meningiomas.

  2010cited by this paper
• Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

  2010cited by this paper
• Imaging of brain tumors: MR spectroscopy and metabolic imaging.

  2010cited by this paper
• Positron emission tomography in patients suffering from HIV-1 infection

  2009cited by this paper
• Pseudoprogression and pseudoresponse in the treatment of gliomas

  2009cited by this paper
• MR Spectroscopy in Radiation Injury

  2009cited by this paper
• Differential diagnosis between radiation necrosis and glioma progression using sequential proton magnetic resonance spectroscopy and methionine positron emission tomography.

  2009cited by this paper
• Early metabolic responses in temozolomide treated low-grade glioma patients

  2009cited by this paper
• Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?

  2009cited by this paper
• Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent.

  2009cited by this paper
• EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2

  2009cited by this paper
• Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements

  2009cited by this paper
• Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study.

  2008cited by this paper
• Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors.

  2008cited by this paper
• Bone involvement predicts poor outcome in atypical meningioma.

  2008cited by this paper
• Bevacizumab for recurrent malignant gliomas

  2008cited by this paper
• Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.

  2008cited by this paper
• Regional Hypoxia in Glioblastoma Multiforme Quantified with [18F]Fluoromisonidazole Positron Emission Tomography before Radiotherapy: Correlation with Time to Progression and Survival

  2008cited by this paper
• Effect of bevacizumab on radiation necrosis of the brain.

  2007cited by this paper
• Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole.

  2007cited by this paper
• Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.

  2007cited by this paper
• Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.

  2007cited by this paper
• Early dynamic 201Tl SPECT in the evaluation of brain tumours

  2006cited by this paper
• Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas

  2006cited by this paper
• Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.

  2006cited by this paper
• Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

  2005cited by this paper
• Diffusion tensor imaging for preoperative evaluation of tumor grade in gliomas.

  2005cited by this paper
• Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings.

  2004cited by this paper

• Post-mortem 11.7 T DTI validation of myeloarchitectural changes in glioblastoma infiltration: Correlation with histology and PLI.

  2025cites this paper